© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
FDA Grants Priority Review to Infigratinib for the Treatment of Cholangiocarcinoma
December 01, 2020
The FDA has accepted a New Drug Application for the oral FGFR1-3 selective inhibitor, infigratinib and granted it Priority Review for the treatment of patients with cholangiocarcinoma.
FDA Approves Pralsetinib for RET+ Thyroid Cancers
December 01, 2020
The FDA approved pralsetinib for the treatment of adult and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy.
Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL
December 01, 2020
During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.
FDA Grants Fast Track Designation to Onivyde in Small Cell Lung Cancer
December 01, 2020
The FDA has granted a Fast Track designation to the irinotecan liposome injection as a potential treatment option for patients with small cell lung cancer who progressed following a first-line platinum-based regimen, Ipsen announced, in a press release.
Exploring How to Get the Best Response in Frontline Multiple Myeloma
December 01, 2020
Caitlin Costello, MD, discusses choosing the optimal first-line therapy for patients with multiple myeloma.
Rolling Submission of BLA to FDA Initiated for Ublituximab Plus Umbralisib in CLL
December 01, 2020
A rolling submission of a Biologics License Application to the FDA has been initiated for the combination of ublituximab plus umbralisib as treatment of patients with chronic lymphocytic leukemia .
Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022
December 01, 2020
The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.
A 66-Year-Old Man With Gastric Carcinoma
December 01, 2020
Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.
FDA Grants Priority Review to Belumosudil for Chronic Graft-Versus-Host Disease
November 30, 2020
The FDA accepted the New Drug Application from belumosudil and granted it a Priority Review designation for the treatment of patients with chronic graft-versus-host disease. The Prescription Drug User Fee Act target action date has been set to May 30, 2021.
Systemic Therapy Advances Provide More Treatment Options in HCC
November 30, 2020
Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.
FDA Grants Fast Track Designation to Eprenetapopt for Treatment of TP53-Mutant AML
November 30, 2020
The FDA granted a Fast Track designation to eprenetapopt as treatment of patients with TP53-mutant acute myeloid leukemia.
Exploring Treatments in Patients With Favorable-Risk RCC
November 30, 2020
During a Targeted Oncology Case Based Peer Perspectives event, Marc Matrana, MD, MS, discussed the case of a 62-year-old male patients with renal cell carcinoma.